Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
NEW ORLEANS, March 04, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 2, 2016 to file lead plaintiff applications in a securities class action lawsuit against PTC Therapeutics, Inc. (Nasdaq:PTCT), if they purchased the Company’s securities between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased shares of PTC and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 2, 2016.
About the Lawsuit
PTC and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 23, 2016, PTC disclosed that it has received a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC’s New Drug Application (NDA) for Translarna for the treatment of muscular dystrophy. PTC further disclosed that the FDA’s Refuse to File letter stated “that the application was not sufficiently complete to permit a substantive review.”
On this news, the price of PTC’s shares plummeted by over 61%.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
